| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCAPI1120 | Aspartame | Aspartame |
|
| DC7360 | AST-1306 | AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
|
| DC11163 | AST-3424 Featured | AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent. |
|
| DC20148 | Astaxanthin | Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is an inhibitor of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity. Astaxanthin has potential in the treatment of various di |
|
| DC23804 | Astex ERK inhibitor X | Astex ERK inhibitor X is a novel potent ERK1/2 inhibitor that inhibits ERK catalytic activity with IC50 of 3 nM in TRK kinase assays. |
|
| DC12617 | Astin C | Astin C is a cyclopeptide isolated from the medicinal plant Aster tataricus, inhibits cGAS-STING signaling and the innate inflammatory responses triggered by cytosolic DNAs, inhibits intracellular DNA-induced Ifnb expression with IC50 of 3.42 and 10.83 uM |
|
| DC8641 | Astragaloside A Featured | Astragaloside A, also known as astragaloside IV, is known to have diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. |
|
| DC11447 | Astragaloside IV Featured | Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. |
|
| DC12126 | Astragaloside VI | Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. |
|
| DC20696 | ASTX660 hydrochloride | ASTX660 hydrochloride is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM. |
|
| DC20695 | ASTX660(Tolinapant） Featured | ASTX660 is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM. |
|
| DC20697 | ASTX660 mesylate | ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM. |
|
| DC7361 | Asunaprevir Featured | Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor. |
|
| DC22401 | AT-090 | AT-090 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 5.61 nM. |
|
| DC20080 | AT-1002 Featured | AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer. |
|
| DC2015 | AT-101 (AT101) | AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members. |
|
| DC26065 | AT-127 Featured | AT-127 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 1.18 nM. |
|
| DC20699 | AT-130 Featured | AT-130 is a potent inhibitor of HBV capsid assembly, inhibits wild-type HBV replication with IC50 of 2.4 uM. |
|
| DC7362 | AT13148 Featured | AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity; AKT, p70S6K, PKA, ROCK, and SGK inhibitor. |
|
| DC8167 | Onalespib（AT13387,ATI13387X） Featured | AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. |
|
| DC20698 | AT-403 | AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45. |
|
| DC7363 | AT-406 Featured | AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively. |
|
| DC7364 | AT-56 Featured | AT-56 is a selective, competitive, and highly bioavailable inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) with a Ki value of 75 µM. |
|
| DC9676 | AT7519 Featured | AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7. |
|
| DC1025 | AT7519 HCL Featured | AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively. |
|
| DC9395 | AT7519 (trifluoroacetate) | AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7. |
|
| DC9336 | AT7867 (dihydrochloride) | AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family. |
|
| DC9335 | AT7867 Featured | AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family. |
|
| DC23554 | AT791 | AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro. |
|
| DC7070 | AT9283 Featured | AT9283 is a small molecule a multi-targeted inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively. |
|
